Allogeneic HSCT offers good survival for select TKI-refractory CML patients
Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Health | Leukemia | Stem Cell Therapy | Stem Cells | Transplants